Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Highlights from EHA 2017:
    2 CML experts give their personal perspectives

    Perspectives on new CML studies from
    Professor Timothy Hughes
    South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

    • Phase II study on dasatinib in children and adolescents with CML-CP
    • 10-year survival results of the German CML IV Study
    • Year 2 results from the British Destiny Study 
    • Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
    • Update on treatment-free remission studies

     

     {rscomments off}